1. Home
  2. ZUMZ vs ZNTL Comparison

ZUMZ vs ZNTL Comparison

Compare ZUMZ & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zumiez Inc.

ZUMZ

Zumiez Inc.

HOLD

Current Price

$13.95

Market Cap

304.2M

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$3.03

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZUMZ
ZNTL
Founded
1978
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
304.2M
289.0M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
ZUMZ
ZNTL
Price
$13.95
$3.03
Analyst Decision
Hold
Buy
Analyst Count
1
5
Target Price
$18.00
$6.60
AVG Volume (30 Days)
304.8K
763.7K
Earning Date
06-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
966.67
18.03
EPS
N/A
N/A
Revenue
$929,057,000.00
N/A
Revenue This Year
$4.30
N/A
Revenue Next Year
$3.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.48
N/A
52 Week Low
$13.07
$1.21
52 Week High
$31.70
$6.95

Technical Indicators

Market Signals
Indicator
ZUMZ
ZNTL
Relative Strength Index (RSI) 30.24 27.05
Support Level N/A $2.09
Resistance Level $18.87 $3.30
Average True Range (ATR) 0.68 0.22
MACD -0.35 -0.06
Stochastic Oscillator 16.90 3.35

Price Performance

Historical Comparison
ZUMZ
ZNTL

About ZUMZ Zumiez Inc.

Zumiez Inc is a United States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art, action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: